药理学 Chapter 1 总论(英文)_第1页
药理学 Chapter 1 总论(英文)_第2页
药理学 Chapter 1 总论(英文)_第3页
药理学 Chapter 1 总论(英文)_第4页
药理学 Chapter 1 总论(英文)_第5页
已阅读5页,还剩85页未读 继续免费阅读

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1DepartmentofPharmacologySchoolofPharmacyPharmacology

WhatisPharmacology?

Chapter1

Introductionbasicmedicine

Pharmacologypharmacymedicine

clinicmedicine2--drugbroadlydefinedasanychemicalthataffectlivingprocesses

--usefulinprevention,diagnosis,

treatmentofdiseases

Chapter1

IntroductionWhatisadrug?3SourcesofDrugsAnimalsPlants

MineralsSyntheticsMicrobesGeneticengineeringdrugs4基因工程药物过程示意图①从细胞中分离出DNA①②③④⑤⑥②限制酶截取DNA片断③分离大肠杆菌中的质粒④DNA重组⑤用重组质粒转化大肠杆菌⑥培养大肠杆菌克隆大量基因

drugTaskofPharmacologymedicinepharamacodynamicspharmacokineticsbody6DevelopmentofPharmacology上古时代公元前1世纪明代(公元1596年)近代药理学的发展迄今7Pharmacological

researchofnewdrugs

pharmacodynamics

generalpharmacology

pharmacokinetics

toxicitology1、preclinicaltestsafetypharmacology8Pharmacological

researchofnewdrugs

Ⅰperiod:20~30caseⅡperiod:200~300case

Ⅲperiod:>400case

Ⅳperiod:clinicaltrial→2000case2、

clinicalpharmacologicaltrial9

Section1

BasicactionofdrugsChapter2

Pharmacodynamicsstimulatorsorexcitantsinhibitorsordepressantsstimulationorexcitation

depressionorinhibitiondrugaction

drugeffect

10

localaction

generalaction

Chapter2

Pharmacodynamicstherapeuticeffectadversdrugreactionselectivity

dualism11Chapter2

Pharmacodynamics

Therapeuticeffect

etiologicaltreatment

symptomatictreatment

12Chapter2

PharmacodynamicsAdversdrugreactionsideaction

econdaryreactiontoxicreactionacutetoxcitychronictoxcitycarcinogenesisteratogenesismutagenesisallergicreactionresidualeffect

withdrawalreaction13

Section2

ReceptivetheoryChapter2

PharmacodynamicsLigand(L)Effect(E)Receptor(R)14Chapter2

Pharmacodynamicsreceptortypechannel-linkdreceptorsG-proteincoupledreceptorstyrosinekinase-linkedreceptorsregulategenetranscriptionreceptors15激动药结合区域膜外膜内激动药结合区域

Ligand-gatedionchannelreceptors16G蛋白偶联CN激动药结合区域膜外膜内

G-proteincoupledrecptors17激动药结合区域膜外膜内催化结构区域

Tyrosine-proteinkinasereceptor18激动药结合区域膜外膜内DNA结合区域转录激活区域载体+药物载体-药物复合物载体

+药物载体

Intracellularreceptors19Chapter2

Pharmacodynamicsreceptorregulationdownregulationupregulationhomospecificregulationheterospecificregulation20Chapter2

PharmacodynamicsLRintrinsicactivityaffinityE21Chapter2

Pharmacodynamicsreceptoragonistfullagonistpartialagonistreceptorantagonist

fullantagonistpartialantagonist2223competitiveantagonist24non-competitiveantagonist25non-competitiveantagonist26drugactionandsignaitransduction27Chapter2

PharmacodynamicsgradedresponsequantalresponseDose-responserelationship28Chapter2

Pharmacodynamicsminimumeffectivedose(thresholddose)maximumeffect(Emax)maximaldose(Max-D)medianeffectivedose(ED50)minimumtoxicdose(Tmin)medianlethaldose(LD50)Dose-responserelationshipefficacypotency29Dose-responserelationshipEmaxED50efficacypotency100%50%thresholddoseMax-DTmin30DoseResponseCurveEmaxEmax31Chapter2

PharmacodynamicsLD50therapeuticindex(TI)

=─────ED50LD5safetyindex(SI)=─────ED95(LD1-ED99)safetymargin(SM)=──────×100%ED99safetyevaluationofdrugs3233Chapter3

Pharmacokinetics

absorptiondistributionmetabolism(biotransformation)excretionSection1

physiologicaldispositionofdrugs34PharmacokineticPhaseelimination35Absorptiondistributionexcretiondrugtransportthroughmembranesmetabolismbiotransformation36

Cellmembrane

1)GIepithelialcells2)vascularendothelium3)bloodbrainbarrier(BBB)

4)subcellularmembranes一、Drugtransportacrossmembranes371234GIepithelialcellsVascularendotheliumBloodbrainbarrier(BBB)Subcellularmembranes38A.

simplediffusion1.

PassivetransportB.

facilitated

diffusionC.

aqueousdiffusion39acrossmembraneoflipidacrossaqueouschannelcarriertransportoutsideinside1.

Passivetransport40

simplediffusion

R=D’A(C1-C2)/XR:

diffusionrate

D’:

diffusion

constantA:

areaofmembrane(C1-C2):

concentrationgradientofdrugsX:

thicknessofmembrane41

Foraweakacid

kaHAH++A-[H+][A-]ka=─────[HA]

ka:dissociationconstantpH=-logconcentration[H+]

-logKaispKa42

Foraweakacid

[A-]pKa=pH-log────

[HA]

[A-]pH-pKa

=

log────

[HA]10pH-pKa=

[A-]/[HA]43Foraweakbase

ka[H+][B]BH+H++BKa=─────

[BH+]

[BH+]pKa–pH=log────[B]10pka–pH=

[BH+]

/

[B]44

Foraweakacid

[unionized]pKa=pH+log───────[ionized]

10PH-pka=[ionized]/[unionized]Foraweakbase

[ionized]pKa=pH+log───────[unionized]

10pka-pH=[ionized]/[unionized]45

If[A-]=[HA]or[B]=[BH+]---pKa=pH

---asubstanceishalfionizedandhalfnonionized

MustbecarefulyoumustknowpKa

[A-]pH-pKa=log───[HA]

[BH+]orpKa–pH=log────[B]46

2.activetransportExamle:Na+-K+ATPase47

3.cytosispinocytosisexocytosis4849

1.Absorption

themovementofadrugfromitssiteofadministrationintothebloodstream二、drugprocessinbodyBloodstreamdrugdrug501)

First-passeffectinfluencingfactorthefirstpasseffectcanbeavoidedby…

sublingualrectuminhalationimsc51GIhepaticportalvein

livervenacava

52

2)Bioavailability

fractionofanadministereddrugthatreachesthesystemiccirculationforIV,Bioavailability=1.0

5354Minimumeffectiveconcentration55

2.DistributionBloodstreamdrugdrugenterstheextracellularfluidsandtissuesofthebodydrugcell56

1)

bindingofdrugbyplasmaproteinsinfluencingfactor2)

bloodstreamoforgan3)

affinityoftissue4)

bloodbrainbarrier5)

placentalbarrier5758ApparentVolumeofDistribution(Vd)Vdishypotheticalvolume

Vd=A/C59

3.Metabolism

twophasesoxidationsreductionshydrolyses

thefirstphase

conjugationsthesecondphase60Hepaticmicrosomalenzymesenzymeinhibitorenzymeinducermixedfunctionoxidases61624.Excretion

excretionofkidneysexcretionofbileexcretionofmammarygland63

Hepatoenteralcirculationliver--bilegallbladder

duodenumexcrete4.Excretion

64消除transportandtransformationofdrugs65

Section2

Basicconcept

ofpharmacokineticsA.

Time-concentrationcurvethresholddoseCmaxTpeakTCmin66

B.HalfLife(t1/2)

firstorderkinetics

t1/2=0.693/Kzeroorderkinetics

t1/2=0.5C/K67C.Drugeliminationrate

dc/dt=-KCn

C:concentrationofthedrugK:eliminationrateconstantn=1firstorderkinetics

-dc/dt=KC1n=0zeroorderkinetics

-dc/dt=KC0=Vmax68

D.

Clearance(CL)CL=Vd.Kor0.693.Vd/t1/2690210123456SteadystateconCss.maxCss.min7

E.Steadystateconcentration(Css)

70血药浓度100200300802460002468100200300时间(半衰期)10020030002460ABC8MTCMEC三种不同给药方案对稳态浓度的影响A.缩短给药时间B.增加给药剂量C.负荷量给药71RoutesofDrugAdministrationcommonabbreviations…po

=peros=oraliv

=intravenous=intotheveinim

=intramuscular=intothemusclesc

=subcutaneous=betweentheskinandmuscleip

=intraperitoneal=withintheperitonealcavityicv

=intracerebroventricular= directlyintotheventricleofthebrain72Chapter4

Factorsaffectingeffectofdrugs

ageandsexmentalandpathologicfactorsindividualvariationandgeneticsspeciesvariationSection1

Factorsaboutorganismaspect73ageandsexage

infants

agedpeople74ageandsexsexmalefemale75mentalfactor

spiritandbodydiseasebodyandspiritdiseaseplaceboactions

mentalandpathologicfactors76

mentalandpathologicfactorspathologicfactordystrophyrenalinadequacyhepaticinadequacy77individualvariationandgeneticfactorsindividualvariationhypersensitivereactiont

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论